KENDALL BUTZ: Open Payments
NPI 1801575543 · WALNUT CREEK, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,958 in 66 payments from 18 companies in 2025. Trend: 2023 $109 · 2024 $1,224 · 2025 $1,958
Food & beverage: $1,930Consulting: $20Education: $8
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 20 | $665 |
| GENZYME CORPORATION | 9 | $276 |
| GlaxoSmithKline, LLC. | 9 | $198 |
| Regeneron Healthcare Solutions, Inc. | 5 | $175 |
| Amgen Inc. | 5 | $138 |
| Ionis Pharmaceuticals, Inc. | 3 | $108 |
| Grifols USA, LLC | 3 | $83 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $52 |
| BioCryst US Sales Co., LLC | 1 | $37 |
| Optinose US, Inc. | 1 | $30 |
Products named: DUPIXENT, FASENRA, TEZSPIRE, NUCALA, DAWNZERA, AIRSUPRA, Xembify, XOLAIR.
Industry payments across CA — which companies pay providers there.
